Loading...
•
Jun 30, 2024
Amneal Q2 2024 Earnings Report
Amneal announced FDA approval for CREXONT® for Parkinson’s disease treatment.
Key Takeaways
Amneal Pharmaceuticals received U.S. FDA approval for CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT is designed to provide a longer duration of 'Good On' time with less frequent dosing compared to immediate-release CD/LD. The commercial launch is planned for September 2024.
CREXONT approved by FDA for Parkinson's disease treatment.
CREXONT delivers more 'Good On' time with less frequent dosing compared to immediate-release CD/LD.
Commercial launch planned in September 2024.
CREXONT consists of IR granules and ER pellets for rapid onset and long-lasting efficacy.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal expects to make CREXONT available to patients in the U.S. in September 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income